Abstract
LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have